Oncology diagnostics growth — The company said 31% year-over-year growth in oncology test volume drove diagnostics revenue, with MRD test volume also rising.
Data licensing deals — Tempus attributed 36% year-over-year growth in Insights revenue and about $200 million in new Data and Applications licenses to large deals with pharma clients.
Product approvals and launches — The company cited FDA approval of the xT Tumor Only assay and the launch of Tempus Preview as operational highlights supporting business momentum.
Raised 2026 revenue guidance
The company raised its 2026 revenue guidance to $1.595 billion-$1.605 billion.
Tempus continues to expect 2026 adjusted EBITDA of about $65 million.
The guidance excludes the impact from the Personalis acquisition, which the company expects to close in late Q4 2026 or early 2027.
TEM•
